公开(公告)号：US20240306988A1

公开(公告)日：2024-09-19

申请号：US18571597

申请日：2022-06-24

申请人： The Regents of the University of California

发明人： Chih-Ming Ho ,  Soban Umar ,  Jure Marijic ,  Michael Zargari ,  Daniel Garcia ,  Jinyoung Brian Jeong

IPC分类号： A61B5/00 ,  A61B5/021 ,  A61K31/137 ,  A61K31/21 ,  A61K31/4468 ,  G16H20/17 ,  G16H40/67

CPC分类号： A61B5/4848 ,  A61B5/021 ,  A61B5/4839 ,  A61B5/7264 ,  A61K31/137 ,  A61K31/21 ,  A61K31/4468 ,  G16H20/17 ,  G16H40/67 ,  A61B2505/03

摘要： Systems and methods for artificial intelligence enable control of hemodynamics in an individual are provided. A number of embodiments use a phenotypic response surface (PRS) that describes a physiological response to a vasopressor and/or a vasodilator to guide administration of the vasopressor and/or vasodilator. Additional embodiments determine an individualized response to but not limited to a vasopressor and/or vasodilator based on the change in pressure to a dose based on a population-based average. Some embodiments continually update the PRS and/or individualized sensitivity based on changes in physiological response to the vasopressor and/or vasodilator.

公开(公告)号：US12065296B2

公开(公告)日：2024-08-20

申请号：US17159924

申请日：2021-01-27

申请人： AMCOR FLEXIBLES NORTH AMERICA, INC.

发明人： Jennifer Riis ,  Yuan Liu ,  Lyndsey A. McMillan ,  Christopher L. Osborn ,  Rishabh Jain

IPC分类号： B65D65/40 ,  A61K9/70 ,  A61K31/167 ,  A61K31/4468 ,  A61K31/465 ,  A61K31/565 ,  B32B7/12 ,  B32B15/085 ,  B32B27/08 ,  B32B27/10 ,  B32B27/30 ,  B32B27/32 ,  B32B27/34 ,  B32B27/36 ,  B65B9/06 ,  B65D65/14

CPC分类号： B65D65/40 ,  A61K9/7023 ,  A61K9/703 ,  A61K31/167 ,  A61K31/4468 ,  A61K31/465 ,  A61K31/565 ,  B32B7/12 ,  B32B15/085 ,  B32B27/08 ,  B32B27/10 ,  B32B27/308 ,  B32B27/32 ,  B32B27/325 ,  B32B27/34 ,  B32B27/36 ,  B65B9/06 ,  B65D65/14 ,  B32B2255/10 ,  B32B2255/26 ,  B32B2307/31 ,  B32B2307/70 ,  B32B2307/7244 ,  B32B2307/7246 ,  B32B2439/40 ,  B32B2439/80 ,  Y10T428/31797

摘要： A film for packaging a product that has a pharmaceutical active agent includes a product-contacting sealing layer. The product contacting layer includes at least 90 wt. % of an ethylene norbornene copolymer having a glass transition temperature in a range from 50° C. to 110° C. The pharmaceutical active agent comprises a Hansen Solubility Parameter for the product-contacting sealing layer of 0.5 or greater.

公开(公告)号：US20240197870A1

公开(公告)日：2024-06-20

申请号：US18537578

申请日：2023-12-12

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Robert C. PORDY ,  Shazia ALI ,  Daniel A. SCHWEMMER GIPE

IPC分类号： A61K39/395 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4468 ,  A61K31/505 ,  A61K39/00 ,  A61P3/06 ,  C07K16/22

CPC分类号： A61K39/3955 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4468 ,  A61K31/505 ,  A61P3/06 ,  C07K16/22 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/56 ,  C07K2317/565

摘要： The present invention provides methods for treating patients suffering from refractory hypercholesterolemia. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin.

公开(公告)号：US20240009342A1

公开(公告)日：2024-01-11

申请号：US18155518

申请日：2023-01-17

申请人： Imbed Biosciences Inc.

发明人： Ankit Agarwal ,  Gaurav Pranami ,  Tyler B. Nelson ,  Anna M. O'Keefe ,  Nicholas L. Abbott ,  Eric Crawford

IPC分类号： A61L15/44 ,  A61K9/70 ,  A61L15/46 ,  A61K31/155 ,  A61K33/40 ,  A61K31/485 ,  A61K33/24 ,  A61K31/445 ,  A61K31/785 ,  A61K33/18 ,  A61K31/4468 ,  A61K31/19 ,  A61K31/381 ,  A61K31/167 ,  A61F13/02 ,  A61K31/713 ,  A61K33/38 ,  A61K47/32 ,  A61L15/18 ,  A61L15/24 ,  C12N15/113

CPC分类号： A61L15/44 ,  A61K9/7007 ,  A61L15/46 ,  A61K31/155 ,  A61K33/40 ,  A61K31/485 ,  A61K33/24 ,  A61K31/445 ,  A61K31/785 ,  A61K33/18 ,  A61K31/4468 ,  A61K31/19 ,  A61K31/381 ,  A61K31/167 ,  A61F13/0289 ,  A61K9/7092 ,  A61K31/713 ,  A61K33/38 ,  A61K47/32 ,  A61L15/18 ,  A61L15/24 ,  C12N15/113 ,  A61L2300/42 ,  A61L2300/41 ,  A61L2300/414 ,  A61F2240/001 ,  A61L2300/104 ,  A61L2300/402 ,  A61L2300/404 ,  A61L2400/12 ,  A61L2420/02 ,  A61L2420/04 ,  A61L2420/08 ,  C12N2310/14

摘要： The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface.

公开(公告)号：US20240009178A1

公开(公告)日：2024-01-11

申请号：US18472127

申请日：2023-09-21

申请人： BioCorRx Pharmaceuticals, Inc.

发明人： Brady J. Granier ,  Jeffrey M. Witkin

IPC分类号： A61K31/4468 ,  A61P25/36

CPC分类号： A61K31/4468 ,  A61P25/36

摘要： The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1:




or a pharmaceutically acceptable salt thereof. Some uses of Compound 1 and/or its stereoisomers include treating a variety of diseases and disorders, including pain, depression, and schizophrenia. In some embodiments, Compound 1 and/or its stereoisomers may be useful in the treatment of a substance use disorder while inducing fewer withdrawal symptoms than a standard-of-care opioid addiction treatment.

公开(公告)号：US11857548B2

公开(公告)日：2024-01-02

申请号：US18118911

申请日：2023-03-08

申请人： BOW RIVER LLC

发明人： Sundar Srinivasan ,  Christina Chow Wallen

IPC分类号： A61K31/496 ,  A61P35/00 ,  A61P35/02 ,  A61P25/18 ,  A61P25/16 ,  A61P35/04 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/502

CPC分类号： A61K31/496 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/0078 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/10 ,  A61K9/2004 ,  A61K9/4841 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4995 ,  A61K31/502 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395 ,  A61P25/16 ,  A61P25/18 ,  A61P35/02 ,  A61P35/04

摘要： The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.

公开(公告)号：US20230346796A1

公开(公告)日：2023-11-02

申请号：US18219783

申请日：2023-07-10

申请人： PAION UK LTD.

发明人： Karin Wilhelm-Ogunbiyi ,  Keith Borkett ,  Gary Stuart Tilbrook ,  Hugh Wiltshire

IPC分类号： A61K31/5517 ,  A61K31/4468 ,  A61K9/00 ,  A61K45/06

CPC分类号： A61K31/5517 ,  A61K9/0019 ,  A61K31/4468 ,  A61K45/06

摘要： The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.

公开(公告)号：US20230346763A1

公开(公告)日：2023-11-02

申请号：US18027840

申请日：2021-09-19

申请人： NANJING KAIWANG PHARMACEUTICAL CO., LTD.

发明人： Shaoping WANG ,  Weining YANG

IPC分类号： A61K31/4468 ,  A61K9/48 ,  A61K9/16

CPC分类号： A61K31/4468 ,  A61K9/4833 ,  A61K9/4866 ,  A61K9/4858 ,  A61K9/16 ,  A61K9/1688

摘要： A method for a pimavanserin solid preparation. The method improves the fluidity of pimavanserin powder during preparation, can improve the stability of the content of an active ingredient in the solid preparation, and has the characteristics of rapid dissolution and release and good compression moldability.

公开(公告)号：US20230293565A1

公开(公告)日：2023-09-21

申请号：US18018782

申请日：2021-07-30

申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

发明人： Thomas HOBMAN ,  Zaikun XU ,  Cheung Pang WONG

IPC分类号： A61K31/7068 ,  A61K31/4468

CPC分类号： A61K31/7068 ,  A61K31/4468

摘要： Use of Wnt/Beta-catenin pathway inhibitors to block replication of SARS-CoV-2 and other pathogenic viruses.

公开(公告)号：US20230285376A1

公开(公告)日：2023-09-14

申请号：US18018031

申请日：2021-07-29

申请人： Amryt Pharmaceuticals Inc.

发明人： Ruth NALLEN ,  Tracy CUNNINGHAM ,  Mark SUMERAY

IPC分类号： A61K31/4468 ,  A61P3/06

CPC分类号： A61K31/4468 ,  A61P3/06

摘要： Provided herein are methods of treating hyperlipidemia or hypercholesterolemia in pediatric patients with lomitapide or a pharmaceutically acceptable salt thereof.